ANI Pharmaceuticals, Inc. (ANIP) — Financial statements
Income statement, balance sheet, and cash flow for ANI Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 883↑43.8% | 614↑26.2% | 487↑53.9% | 316↑46.4% | 216 | |
| Cost of Revenue | 433↑72.9% | 250↑37.8% | 182↑30.8% | 139↑37.9% | 101 | |
| Gross Profit | 451↑23.7% | 364↑19.3% | 305↑71.9% | 178↑53.7% | 116 | |
| Operating Expenses | ||||||
| R&D Expenses | 52↑15.9% | 45↑30.0% | 34↑53.6% | 22↑96.3% | 11 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 318↑27.3% | 250↑54.4% | 162↑30.4% | 124↑47.2% | 84 | |
| Other Expenses | 0.00↓100.0% | 69↑11.3% | 62↓6.3% | 67↑11.5% | 60 | |
| Operating Expenses | 369↑1.6% | 364↑40.7% | 258↑21.3% | 213↑37.1% | 155 | |
| Total Costs & Expenses | 802↑30.7% | 614↑39.5% | 440↑25.1% | 352↑37.4% | 256 | |
| Operating Results | ||||||
| Operating Income | 81↑13809.2% | 0.58↓98.8% | 47↑233.1% | -35↑11.3% | -40 | |
| Depreciation & Amortization | 91↑35.0% | 68↑13.3% | 60↑0.2% | 60↑26.2% | 47 | |
| EBITDA | 207↑228.4% | 63↓40.8% | 107↑325.7% | 25↑703.6% | 3 | |
| EBIT | 116↑2613.0% | -5↓109.8% | 47↑235.2% | -35↑21.6% | -44 | |
| Interest & Other Income | ||||||
| Net Interest Income | -20↓14.0% | -18↑34.7% | -27↑4.0% | -28↓135.3% | -12 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 20↑14.0% | 18↓34.7% | 27↓4.0% | 28↑135.3% | 12 | |
| Non-Operating Income | -35↓766.6% | 5↑3166.7% | 0.16↑123.7% | -0.67↓115.4% | 4 | |
| Other Income / Expenses | 15↑163.9% | -23↑15.9% | -27↑1.0% | -27↓68.3% | -16 | |
| Income Before Tax | 96↑531.3% | -22↓211.8% | 20↑131.7% | -63↓11.8% | -56 | |
| Income Tax Expense | 17↑573.0% | -4↓437.6% | 1↑107.4% | -15↓9.8% | -13 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 78↑522.9% | -19↓198.6% | 19↑139.2% | -48↓12.4% | -43 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 78↑522.9% | -19↓198.6% | 19↑139.2% | -48↓12.4% | -43 | |
| Bottom-Line Net Income | 71↑450.3% | -20↓217.4% | 17↑134.6% | -50↓15.7% | -43 | |
| EPS (Basic) | 3.50↑436.5% | -1.04↓209.5% | 0.95↑131.1% | -3.05↑10.3% | -3.40 | |
| EPS (Diluted) | 3.32↑419.2% | -1.04↓210.6% | 0.94↑130.8% | -3.05↑10.3% | -3.40 | |
| Weighted Average Shares | 20↑3.8% | 19↑7.3% | 18↑10.7% | 16↑29.1% | 13 | |
| Weighted Average Diluted Shares | 21↑9.9% | 19↑6.2% | 18↑11.9% | 16↑29.1% | 13 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.